Nektar Therapeutics (NASDAQ: NKTR) kicked off on Friday, up 4.98% from the previous trading day, before settling in for the closing price of $0.74. Over the past 52 weeks, NKTR has traded in a range of $0.43-$1.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -0.50%. While this was happening, its average annual earnings per share was recorded -13.65%. With a float of $179.37 million, this company’s outstanding shares have now reached $185.78 million.
The extent of productivity of a business whose workforce counts for 61 workers is very important to gauge. In terms of profitability, gross margin is 68.82%, operating margin of -92.39%, and the pretax margin is -121.1%.
Nektar Therapeutics (NKTR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nektar Therapeutics is 3.62%, while institutional ownership is 69.45%. The most recent insider transaction that took place on Feb 19 ’25, was worth 10,403. In this transaction Chief R&D Officer of this company sold 10,300 shares at a rate of $1.01, taking the stock ownership to the 316,604 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Legal Officer sold 11,040 for $1.01, making the entire transaction worth $11,150. This insider now owns 324,292 shares in total.
Nektar Therapeutics (NKTR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.48% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Take a look at Nektar Therapeutics’s (NKTR) current performance indicators. Last quarter, stock had a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.58, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.80 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
The latest stats from [Nektar Therapeutics, NKTR] show that its last 5-days average volume of 1.77 million was inferior to 2.27 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 89.94%. Additionally, its Average True Range was 0.07.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 42.09%, which indicates a significant decrease from 90.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 114.17% in the past 14 days, which was higher than the 90.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7700, while its 200-day Moving Average is $1.0621. Now, the first resistance to watch is $0.8107. This is followed by the second major resistance level at $0.8464. The third major resistance level sits at $0.8814. If the price goes on to break the first support level at $0.7400, it is likely to go to the next support level at $0.7050. Assuming the price breaks the second support level, the third support level stands at $0.6693.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
The company with the Market Capitalisation of 144.25 million has total of 186,104K Shares Outstanding. Its annual sales at the moment are 98,430 K in contrast with the sum of -118,960 K annual income. Company’s last quarter sales were recorded 29,180 K and last quarter income was 7,260 K.
